"Nasopharyngitis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inflammation of the NASOPHARYNX, usually including its mucosa, related lymphoid structure, and glands.
| Descriptor ID |
D009304
|
| MeSH Number(s) |
C07.550.350.700 C07.550.781.500 C08.730.561.500 C09.775.350.700 C09.775.649.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nasopharyngitis".
Below are MeSH descriptors whose meaning is more specific than "Nasopharyngitis".
This graph shows the total number of publications written about "Nasopharyngitis" by people in this website by year, and whether "Nasopharyngitis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 3 | 3 |
| 2018 | 1 | 3 | 4 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Nasopharyngitis" by people in Profiles.
-
Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations. J Am Acad Dermatol. 2020 Jul; 83(1):e31.
-
Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020 05; 82(5):1217-1218.
-
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019 Jun; 6(6):e295-e305.
-
High HLA-F Expression Is a Poor Prognosis Factor in Patients with Nasopharyngeal Carcinoma. Anal Cell Pathol (Amst). 2018; 2018:7691704.
-
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018 03 15; 20(1):47.
-
Guselkumab for the treatment of psoriasis. Expert Opin Biol Ther. 2018 04; 18(4):459-468.
-
In reply to "Commentary to: Endoscopic and clinical benefits of hyaluronic acid in children with chronic adenoiditis and middle ear disease", by Zhengcai Lou. Eur Arch Otorhinolaryngol. 2018 03; 275(3):829-830.
-
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017 11 01; 56(11):1993-2003.
-
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for =156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017 Aug; 77(2):310-317.e1.
-
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. Gastroenterology. 2017 Jul; 153(1):77-86.e6.